Browse the evidence

High-fat diets induce a pro-inflammatory phenotype in neutrophils and their bone marrow progenitors via NLRP3 inflammasome activation and IL-1b signaling, contributing to systemic low-grade inflammation and insulin resistance.

Your immune system is listening to what you eat. Diets high in certain fats can program your white blood cells to stay in a state of low-grade alert, which contributes to insulin resistance and heart disease risk. Choosing healthier fat profiles (like unsaturated fats) may help keep these immune cells from becoming over-activated.

Short-chain fatty acids (SCFAs) like butyrate and acetate have complex, site-specific effects on neutrophils, potentially promoting anti-inflammatory or pro-resolutive functions depending on the context and receptor interaction (e.g., FFAR2).

Fiber-rich foods produce short-chain fatty acids (SCFAs) in your gut, which can have beneficial, anti-inflammatory effects on your immune system. Including fiber in your diet supports these healthy fat-derived signals.

Saturated fatty acids (e.g., palmitate) promote neutrophil extracellular trap (NET) formation and NLRP3 inflammasome activation, whereas unsaturated fatty acids (e.g., oleic, linoleic, omega-3s) tend to inhibit these pro-inflammatory pathways.

The type of fat you eat matters for inflammation. Saturated fats can trigger inflammatory responses in white blood cells, while unsaturated fats (found in olive oil, fish, nuts) can help suppress these responses.

Eating Disorder (ED) diagnosis is significantly associated with amenorrhea in resistance-trained athletes, consistent with Relative Energy Deficiency in Sport (REDs) models.

If you have an eating disorder diagnosis, you are at higher risk for missing periods (amenorrhea). This is a sign of Relative Energy Deficiency in Sport (REDs). Addressing energy availability is crucial for restoring menstrual function and long-term health.

Higher levels of the satiety hormone GLP-1 are associated with lower salt taste preference specifically following a low-fat diet.

When eating a low-fat diet, higher levels of the gut hormone GLP-1 are associated with a lower preference for salty foods. This suggests that GLP-1 may play a role in modulating salt taste preferences specifically in the context of low-fat eating.

Maintaining serum Lipoprotein(a) [Lp(a)] levels below 298 mg/L is associated with a delay in the progression of coronary artery disease severity.

If you have heart disease, ask your doctor to check your Lipoprotein(a) level. The study suggests keeping it below 298 mg/L. Unlike other cholesterol markers, Lp(a) is largely genetic and doesn't drop significantly with diet or exercise alone, so you may need specific medical therapies to manage it.

Obesity pathogenesis is driven by a complex network of 802 core genetic risk genes that function through integrated neurological (appetite regulation, synaptic signaling) and metabolic (lipid/glucose homeostasis) pathways.

Obesity is not just a lifestyle choice; it is heavily influenced by your genetics. If you have a family history of obesity, your body may regulate appetite and metabolism differently. This doesn't mean you can't lose weight, but it means you may need more targeted strategies, such as medical interventions that address specific hormonal pathways (like GLP-1 or MC4R agonists), rather than relying on standard diet advice alone.

Obesity-risk genes are highly expressed in specific cell types: hypothalamic neurons (regulating appetite), pancreatic beta-cells (regulating insulin), adipocytes (lipid homeostasis), and hepatocytes (lipid metabolism).

Obesity affects multiple organs. Your brain (hypothalamus) controls hunger, your pancreas controls insulin, your fat cells store energy, and your liver processes fats. Effective treatment often needs to address these specific tissues, which is why drugs like GLP-1 agonists (which act on the brain and pancreas) are effective.

Ultra-processed foods drive obesity primarily through rapid digestion of carbohydrates leading to metabolic swings and hunger, not through hyper-palatability or tastiness.

Focus on the metabolic impact of food processing rather than just taste. Choose minimally processed foods where the food matrix slows digestion (like whole fruits vs. sugar, or wheat berries vs. white bread). This helps stabilize blood glucose and insulin, reducing the hunger signals that drive overconsumption, regardless of how 'tasty' the food is.

Long-term use of inhaled corticosteroids (ICS) with standard-sized particles increases the risk of developing OSA due to pharyngeal muscle atrophy and neck fat redistribution, whereas extra-fine particles do not show this increased risk.

If you use standard inhaled corticosteroids and have sleep apnea, ask your doctor about switching to extra-fine particle formulations. These may reduce the risk of worsening sleep apnea while still controlling your asthma, as they deposit deeper in the lungs rather than the throat.

GLP-1 receptor agonists are an acceptable adjunct to progestin therapy for fertility preservation in young patients with endometrial cancer or atypical hyperplasia, provided they are framed as medically indicated treatment for cancer and fertility rather than cosmetic weight loss.

If you are a young woman with endometrial cancer or atypical hyperplasia and want to preserve fertility, GLP-1 medications like Semaglutide or Tirzepatide can be a helpful tool alongside progestin therapy. However, you must have a clear, honest conversation with your doctor about the costs, potential side effects, and a plan to keep the weight off after stopping the drug. Framing the medication as a medical treatment for your cancer and fertility, rather than just for weight loss, can help you feel more comfortable and less stigmatized.

Post-bariatric surgery weight regain (affecting 15-20% of patients) can be managed with endoscopic interventions or OMM, but optimal dosing and scheduling for these combination therapies remain undefined.

If you regain weight after surgery (affecting 15-20% of patients), you are not out of options. Endoscopic procedures or adding back medications like GLP-1s can help, but doctors currently lack clear guidelines on the best doses and schedules for this specific scenario.

In obese individuals, a combined metabolic index of insulin (INS) and free fatty acids (FFAs) effectively predicts the presence of subclinical left ventricular hypertrophy (LVH), serving as a practical prescreen for early cardiac remodeling risk.

If you are obese, standard blood work might miss early heart strain. Ask your doctor about checking insulin and free fatty acids alongside standard lipids. This combination can flag heart thickening (LVH) before your heart's pumping ability drops, allowing for earlier lifestyle or medical intervention.

Triglycerides (TG) are the most robust independent predictor of the continuous burden of left ventricular mass (LVM) in obesity, whereas insulin and FFAs predict the threshold transition to hypertrophy.

High triglycerides are a strong indicator of increasing heart muscle mass in obesity. Monitoring TG levels can help track the gradual structural load on the heart, even if blood pressure and pumping function seem normal.

High daily consumption of carbohydrates (>60% of total energy) and simple sugars (>10% of total energy) is associated with a statistically significant increase in breast cancer risk.

To potentially lower breast cancer risk, aim to keep carbohydrate intake below 60% of your total daily energy and ensure simple sugars (added sugars) do not exceed 10% of your total energy. Focus on reducing refined sugars and high-glycemic carbohydrates, as high intake of these is linked to a significantly higher risk of developing breast cancer in this study.

Higher salt taste preference is positively correlated with systolic blood pressure, body weight, and BMI following consumption of an ultra-processed diet.

If you prefer salty foods and eat an ultra-processed diet, you may have higher blood pressure and body weight. Monitoring your salt preference and overall diet quality might be beneficial.

Dermal white adipose tissue (dWAT) loss and fibrotic transformation due to aging and photodamage reduce adiponectin production, leading to compromised skin health, fine lines, and atrophy.

Prioritize skin health by maintaining healthy dermal fat. Avoid aggressive fat-destroying procedures if possible, as loss of dermal white adipose tissue (dWAT) leads to fibrosis, reduced adiponectin, and faster skin aging. Focus on treatments that support or regenerate small, healthy fat cells rather than just removing volume.

GLP-1 receptor agonists (GLP-1RAs) cause facial fat atrophy, sagging, and wrinkling ("Ozempic face") by inhibiting adipocyte differentiation and promoting fibrotic transformation of dWAT.

If using GLP-1RAs, be aware that facial fat loss and skin aging ('Ozempic face') are common side effects. Consider proactive skin care or aesthetic interventions (like fat grafting or regenerative fillers) to counteract fat loss and fibrosis. Monitor facial changes and discuss mitigation strategies with your provider.

Hypertrophic (large) adipocytes promote skin aging by secreting proinflammatory cytokines, downregulating collagen/elastin, and upregulating MMPs, whereas small healthy adipocytes promote skin health via adiponectin.

Maintain a healthy weight to avoid hypertrophic (large) fat cells, which promote skin aging through inflammation and collagen breakdown. Focus on strategies that promote small, healthy fat cells, which support skin structure via adiponectin.

Long-term adherence to low-carbohydrate diets may attenuate weight loss benefits and potentially increase LDL cholesterol in some individuals, raising cardiovascular risk concerns.

While LCDs work well for short-term weight loss, be aware that benefits may diminish after a year, and some people see their bad cholesterol (LDL) rise. Regular monitoring of lipids and liver health is essential if you stay on this diet long-term.

The weight loss benefit of tirzepatide over semaglutide is significantly attenuated or absent in patients with type 2 diabetes compared to those without diabetes.

For patients with diabetes, the weight loss advantage of tirzepatide over semaglutide seen in non-diabetics may not be present. Consult your doctor to manage expectations regarding weight loss if you have diabetes.

Genetic variability in the GLP1R gene can lead to non-response to GLP-1 receptor agonists in some patients with T2DM and obesity.

Some patients with T2DM and obesity do not respond well to GLP-1 receptor agonists due to genetic factors. If you are not seeing results, genetic variability in the GLP-1 receptor might be a cause. Discuss this with your healthcare provider to explore other treatment options or lifestyle interventions.

GLP-1 receptor agonists delay gastric emptying and increase the risk of pulmonary aspiration during general anesthesia, necessitating specific peri-operative management strategies.

If you take a GLP-1 drug (like Ozempic, Wegovy, or Trulicity) and have surgery, tell your anesthesiologist. You likely need to stop the drug for a specific time before surgery (often 3 half-lives, e.g., 1 week for weekly drugs) to prevent stomach contents from entering your lungs while asleep. Do not assume standard fasting rules apply; your stomach may still be full even if you haven't eaten for 12 hours.

Semaglutide improves insulin sensitivity and glucose uptake in skeletal muscle and adipose tissue by activating the PI3K/AKT and AMPK/SIRT1 pathways, leading to GLUT4 translocation, independent of direct insulin action in some contexts.

Semaglutide helps your body use insulin better by activating specific cellular pathways (AMPK/SIRT1) that move glucose into muscles and fat cells. This reduces insulin resistance, a key factor in type 2 diabetes and obesity.